Latest in Science

Image credit:

Google teams up with GSK to develop 'bioelectronic medicines'

Galvani Bioelectronics' first project will look into the treatment of type 2 diabetes.
Matt Brian, @m4tt
August 1, 2016
Share
Tweet
Share

Sponsored Links

By forcing startups like Google X, Fiber and Nest to behave like companies and take financial accountability, Alphabet believes that its subsidiaries are more likely to invest in projects that will ultimately make it money. Being in the expensive healthcare business, Verily -- formerly Google Life Sciences -- often needs to speculate to accumulate, but for its latest venture, the company is dreaming big. It's teaming up with British pharmaceutical giant GlaxoSmithKline (GSK) to develop bioelectronic medicines that can "harness electrical signals in the body to treat chronic disease."

Under the agreement, both companies will invest up to £540 million ($715 million) to form a new company, Galvani Bioelectronics. It's named after Luigi Aloisio Galvani, an 18th century Italian scientist who was one of the early pioneers of bioelectricity (he was also the guy who found that frogs legs twitch when exposed to an electric current). According to GSK's press release, it'll be headquartered in the UK, with a second research hub in San Francisco, and will primarily focus on the "research, development and commercialization" of bioelectronics.

GSK believes that biomedicines can treat conditions like arthritis and asthma, but one of Galvani Bioelectronics' first projects will focus on the development of "miniaturised precision devices" that can help remedy "inflammatory, metabolic and endocrine disorders" including type 2 diabetes. GSK will fuse its drug discovery and development prowess with Verily's expertise in developing tiny low power electronics.

Initially, Galvani will employ 30 scientists, engineers and clinicians, who will utilise treatments developed by both parent companies, academic institutions and other R&D companies. They'll have to wait until the deal is approved by competition regulators before they do, but both parties expect that to happen before the end of the year.

All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, we may earn an affiliate commission.
Comment
Comments
Share
Tweet
Share

Popular on Engadget

Google's work from home strategy includes a $1,000 allowance

Google's work from home strategy includes a $1,000 allowance

View
Philips Hue leaks show new versatility for Lightstrip Plus and Bloom

Philips Hue leaks show new versatility for Lightstrip Plus and Bloom

View
LG's first 48-inch 4K OLED TV is starting to roll out

LG's first 48-inch 4K OLED TV is starting to roll out

View
Google adds 1440p streaming resolution for Stadia on Chrome

Google adds 1440p streaming resolution for Stadia on Chrome

View
Making an indie phone is not for the faint-hearted

Making an indie phone is not for the faint-hearted

View

From around the web

Page 1Page 1ear iconeye iconFill 23text filevr